Acute generalized exanthematous pustulosishttps://en.wikipedia.org/wiki/Acute_generalized_exanthematous_pustulosis
Acute generalized exanthematous pustulosis (AGEP) ukusabela kwesikhumba okungajwayelekile, okungama-90 % ezimweni kuhambisana nokusetshenziswa kwemithi. I-Acute generalized exanthematous pustulosis ibonakala ngokuvuka kwesikhumba okungazelelwe, okuqala phakathi kwezinsuku ezinhlanu ngemva kokuqala kokuthatha umuthi. Lokhu kuveza ama-pustules, okungukuthi ama-pustules amancane, amhlophe noma abomvu, agcwele umphunga noma i-purulent (ubovu). Izilonda zesikhumba zivame ukuphola phakathi kwezinsuku ezingu-1‑3 ngemva kokuyeka imithi ebangela lesi sifo.

☆ AI Dermatology — Free Service
Emiphumeleni ka-2022 ye-Stiftung Warentest evela eJalimane, ukwaneliseka kwabathengi nge-ModelDerm bekungaphansi kancane kunokuxhumana okukhokhelwayo kwe-telemedicine.
  • Izilonda ezisabalele nge-erythema nama-pustules zivela ngokuzumayo.
  • I‑erythema kanye ne‑pustules ngaphandle kokulunywa kwenzeka ngokuzumayo.
References Acute Generalized Exanthematous Pustulosis 37276304 
NIH
I-Acute generalized exanthematous pustulosis (AGEP) wukusabela kwesikhumba okubangelwa amaqhaku amancane agcwele ubomvu esikhunjeni. Ngokuvamile kwenzeka lapho umuntu ethatha imithi ethile, njengama‑antibiotics, futhi lesi sifo sasicindezela ngokushesha kuwo wonke umzimba. Ngemuva kokuyeka imithi ebangele lesi sifo, izimpawu ngokuvamile ziyaphela phakathi kwamaviki amabili, futhi kuvame ukuhamba nesikhumba esishiywe yizindawo ezibomvu. Nakuba ngokuvamile leli sifo lingabanga ubungozi futhi lilawuleka esikhumbeni, izimo ezinzima zingavela, njenge‑Stevens‑Johnson syndrome noma i‑toxic epidermal necrolysis. Ukwelashwa ngokuyinhloko kugxile ekunakekelweni okusekelayo, futhi ukubikezela ukuphola kwalesi sifo kuvame ukuba kuhle kakhulu.
Acute generalized exanthematous pustulosis (AGEP) is an adverse cutaneous reaction characterized by sterile pinpoint nonfollicular pustules atop an erythematous background. Symptoms most often occur in the setting of medication exposure, such as systemic antibiotics, rapidly become generalized, followed by desquamation and resolution within about two weeks of discontinuing the offending trigger. Although mostly self-limited without systemic involvement, severe cases are classified alongside other cutaneous adverse reactions such as Stevens-Johnson syndrome, toxic epidermal necrolysis, and drug reaction with eosinophilia and systemic symptoms. Treatment is primarily supportive, and the prognosis for complete resolution is excellent.
 Acute Generalized Exanthematous Pustulosis: Clinical Characteristics, Pathogenesis, and Management 36702114
Recent experimental data reviewed herein are supportive of an early role of drug-induced innate immune activation and innate cytokines such as interleukin (IL)-1, IL-36, and IL-17 in the pathogenesis of AGEP. This explains the rapid onset and neutrophilic character of the cutaneous inflammation.
 Acute Generalized Exanthematous Pustulosis - Case report 36876416 
NIH
Ikhehla elineminyaka engu-76 ubudala lafika egunjini labezimo eziphuthumayo ngenxa yokuthi isikhumba salo sase sishintshile ezinsukwini ezimbili ezedlule. Odokotela bathola amabala abomvu futhi baphakamisa izindawo esiqwini sakhe nasezingalweni nasemilenzeni. Ngokuhamba kwesikhathi, la mabala ahlangana ndawonye, ​​futhi waba namaqhubu anjengezinduna ezindaweni ezibomvu. Ukuhlola kubonise inani eliphezulu lamaseli amhlophe egazi anohlobo oluningi olubizwa ngokuthi ama-neutrophils, kanye namazinga anyusiwe angu- C-reactive protein.
A 76-year-old male patient presented as an emergency due to a 2-day history of skin changes. Physical examination revealed disseminated erythematous macules and plaques on the trunk and extremities. In the further course, confluence of the macules and non-follicular pustulosis developed in the area of erythema. Laboratory tests revealed leukocytosis with neutrophils and elevated C-reactive protein.